Kathleen Moore details outcome measures from three major phase III trials—KEYNOTE-B96, ROSELLA, and MIRASOL—highlighting objective response rates, progression-free and overall survival, and key safety signals. Leaners will be provided a comparison of results across different patient populations and study endpoints, along with practical insight into how these data translate into everyday clinical practice. This presentation also highlights the clinical relevance and real-world feasibility of integrating these emerging regimens into treatment pathways. Presented by:
Kathleen N. Moore, MDProfessor, Division of Gynecologic Oncology at University of OklahomaDeputy Director, Stephenson Cancer Center at University of OklahomaUSA
Moderated by:
Wendel Naumann, MD Director of Minimally Invasive Surgery in Gynecologic Oncology Carolinas Medical CenterAssociate Medical Director of Clinical Trials Levine Cancer Institute, Atrium Health USA
Floor Backes, MDThe Ohio State University Wexner Medical CenterJames Comprehensive Cancer CenterUSA